Healthcare business law · Updated
DEA telemedicine prescribing after December 31, 2026: what ends, what stays and what may replace it
Until the end of the day on December 31, 2026, a DEA-registered practitioner may prescribe Schedule II-V controlled substances by telemedicine to a patient the practitioner has never examined in person, if the prescription is for a legitimate medical purpose, is issued through an interactive telecommunications system, and meets DEA's other prescription rules (21 CFR 1307.41). That permission comes from a temporary rule, the fourth extension of the COVID-19 telemedicine flexibilities, and it ends on its own terms. As of November 16, 2026, DEA has not published a fifth extension or a final special registration rule. Two separate final rules, in our reading, continue after December 31: buprenorphine for opioid use disorder by telemedicine, and telemedicine prescribing by VA practitioners to VA patients. Otherwise, in our reading, prescribing a controlled substance by telemedicine without an in-person evaluation will again need one of the narrow routes in the Ryan Haight Act. Prescriptions for drugs that are not controlled substances are not affected.
| Situation | Through December 31, 2026 | From January 1, 2027, if DEA publishes nothing new (our reading) |
|---|---|---|
| New patient, never examined in person, Schedule II-V | Allowed if the four conditions of 21 CFR 1307.41(c) are met | Needs an in-person medical evaluation, a covering practitioner, or one of the telemedicine categories in 21 U.S.C. 802(54) |
| Patient the prescriber has examined in person at least once | Allowed | Allowed: a "valid prescription" under 21 U.S.C. 829(e)(2) |
| Covering practitioner for a colleague who is temporarily unavailable | Allowed | Allowed if the colleague evaluated the patient in person, or through the practice of telemedicine, within the previous 24 months (829(e)(2)(C)) |
| Buprenorphine for opioid use disorder | Allowed under the temporary rule or the buprenorphine final rule | The final rule continues: an initial six-month supply by telemedicine, including audio-only, after a check of the patient's state prescription drug monitoring program |
| VA practitioner and VA patient | Allowed | The VA final rule continues where another VA practitioner has examined the patient in person at any time, subject to its conditions |
| Patient treated in a DEA-registered hospital or clinic, or in the physical presence of a DEA-registered practitioner | Allowed | Allowed as the practice of telemedicine (802(54)(A), (B)), with DEA registration in the patient's state as the statute requires |
| Drugs that are not controlled substances | Not governed by these DEA rules | Not governed by these DEA rules; state law applies |
| Document | Status | What it does |
|---|---|---|
| Fourth temporary extension, 90 FR 61301 (December 31, 2025) | In effect January 1 through December 31, 2026 | Amends 21 CFR 1307.41 and 42 CFR 12.1 to allow Schedule II-V prescribing by telemedicine without an in-person evaluation |
| Buprenorphine final rule, 90 FR 6504 (January 17, 2025) | In effect since December 31, 2025 | Telemedicine prescribing of Schedule III-V medications approved for opioid use disorder; separate from the temporary rule |
| VA final rule, 90 FR 6523 (January 17, 2025) | In effect since December 31, 2025 | Telemedicine prescribing by VA practitioners to VA patients; separate from the temporary rule |
| Special registration proposed rule, 90 FR 6541 (January 17, 2025) | Proposed; comments closed March 18, 2025; no final rule published | Three types of special registration, a DEA-issued State Telemedicine Registration for each patient state, and limits on Schedule II |
| 21 U.S.C. 831(h)(2) | Statute | Required final special registration regulations "Not later than 1 year after October 24, 2018" |
Where things stand on November 16, 2026
We checked the Federal Register on November 16, 2026. The newest DEA rule on telemedicine prescribing is still the fourth temporary extension, published December 31, 2025 (90 FR 61301). DEA has not published a fifth extension or a final rule on special registration for telemedicine, and no DEA document was on public inspection for November 17 (Federal Register). DEA's own Diversion Control telemedicine page says that "DEA is in the process of drafting updated regulations for telemedicine" (DEA). Silence in November is not a signal either way: the fourth extension was itself published on December 31, 2025, the last day of the third. We update this page when DEA publishes anything new.
The baseline: the Ryan Haight Act
As DEA summarizes it, the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 "generally requires an in-person medical evaluation prior to the issuance of a prescription of controlled substances" (90 FR 6541). The rule sits in 21 U.S.C. 829(e): no controlled substance that is a prescription drug "may be delivered, distributed, or dispensed by means of the Internet without a valid prescription." A valid prescription is one issued "for a legitimate medical purpose" "in the usual course of professional practice" by "a practitioner who has conducted at least 1 in-person medical evaluation of the patient", or by a covering practitioner. An in-person evaluation is one "conducted with the patient in the physical presence of the practitioner", and the statute adds that one such evaluation does not by itself show a legitimate medical purpose.
The exception is the "practice of telemedicine", which 21 U.S.C. 802(54) limits to seven situations: the patient is being treated in, and is physically located in, a DEA-registered hospital or clinic; the patient is in the physical presence of a DEA-registered practitioner; Indian Health Service and tribal practitioners designated as Internet Eligible Controlled Substances Providers; a public health emergency declared by the HHS Secretary, for areas and substances the Secretary designates; a practitioner holding a "special registration" under 21 U.S.C. 831(h); a VA medical emergency, "limited to a maximum of a 5-day supply"; and "any other circumstances that the Attorney General and the Secretary have jointly, by regulation," determined "to be consistent with effective controls against diversion". In the first two, the practitioner must generally be registered "in the State in which the patient is located".
The fourth extension refers to the HHS Secretary's "rulemaking authority under 21 U.S.C. 802(54)(G)", the last category. The special registration is the route Congress told DEA to build: "Not later than 1 year after October 24, 2018," the Attorney General "shall promulgate final regulations" setting out when a special registration may be issued and how to obtain one (21 U.S.C. 831(h)(2)). No final special registration rule has been published.
What the temporary rule allows until December 31
"During the period May 12, 2023, through December 31, 2026, a DEA-registered practitioner is authorized to prescribe schedule II-V controlled substances via telemedicine, as defined in 21 CFR 1300.04(i), to a patient without having conducted an in-person medical evaluation of the patient" if all four conditions are met (21 CFR 1307.41, as amended by 90 FR 61301):
- "The prescription is issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice";
- it is issued "pursuant to a communication between a practitioner and a patient using an interactive telecommunications system referred to in 42 CFR 410.78(a)(3)";
- the practitioner's DEA registration authorizes "the basic class of controlled substance specified on the prescription", or the practitioner is exempt from registration under 21 U.S.C. 822(d); and
- "The prescription is consistent with all other requirements of 21 CFR part 1306."
Why it ends and what DEA said
The section "is in effect until the end of the day December 31, 2026." DEA and HHS issued the fourth extension "without prior notice and an opportunity to comment". They explained that DEA "received over 6,475 comments" on the special registration proposal and needed time "to thoroughly consider the presentations made at the Telemedicine Listening Sessions", and that "the extension will provide time for DEA to promulgate a final set of regulations." The rule describes its purpose as preventing the "telemedicine cliff": "the reinstatement of the pre-pandemic restrictions imposed by the CSA". It does not say whether another extension will follow (90 FR 61301).
What continues after December 31: buprenorphine and VA patients
Two final rules published January 17, 2025 took effect December 31, 2025, after two delays (90 FR 13410). They are separate from the temporary rule and, in our reading, do not expire with it.
The buprenorphine rule lets DEA-registered practitioners prescribe "schedule III-V controlled substances approved by the Food and Drug Administration for the treatment of opioid use disorder via a telemedicine encounter, including an audio-only telemedicine encounter." After reviewing prescription drug monitoring program data "for the state in which the patient is located during the telemedicine encounter", the practitioner "may prescribe an initial six-month supply", split among several prescriptions. Later prescriptions need "other forms of telemedicine as authorized under the Controlled Substances Act" or an in-person evaluation, and the pharmacist must "verify the identity of the patient prior to filling a prescription" (90 FR 6504).
The VA rule lets VA practitioners prescribe controlled substances by telemedicine to a VA patient they have not examined in person "if another VA practitioner has, at any time, previously conducted an in-person medical evaluation of the VA patient", "subject to certain conditions" (90 FR 6523).
What could replace it: the special registration proposal
DEA's proposal of January 17, 2025 would "establish a Special Registration framework" with three types: a Telemedicine Prescribing Registration for clinicians "to prescribe Schedule III-V controlled substances via telemedicine"; an Advanced Telemedicine Prescribing Registration "to prescribe Schedule II-V controlled substances via telemedicine"; and a Telemedicine Platform Registration for "covered online telemedicine platforms" (90 FR 6541). A special registrant would need "a State Telemedicine Registration for every state in which a patient is treated", which "would be issued by DEA, not the states". DEA proposed a fee of $888 for any of the three registrations. A Schedule II prescription under a special registration could be issued only if the clinician "is physically located in the same state in which the patient was located", and such prescriptions would have to be less than 50 percent of the clinician's Schedule II prescriptions in a calendar month (proposed 21 CFR 1306.45). Comments closed March 18, 2025.
It is a proposal, not law. A final rule may differ on every point above, and none of it applies until a final rule is published and takes effect.
DEA registration in the patient's state
The in-person question is separate from the registration question. DEA's guidance says "practitioners generally must be registered with DEA in a patient's state to prescribe controlled substances to that patient via telemedicine, but a number of exceptions to that requirement exist", and notes that guidance documents "are not binding" (DEA, July 28, 2020). For patients in North Carolina the Medical Board says the same: "Unless an exception exists, the DEA requires all prescribers to hold a state-specific DEA registration in the state where the patient is located at the time of care", and North Carolina has no separate state controlled-substance registration (NCMB). The temporary rule's conditions do not say in which state the practitioner's registration must be held. In our reading, a multi-state platform should confirm a registration in each patient's state now rather than treat December 31 as the only date that matters.
Who this reaches
Only controlled substances. A business that prescribes only drugs that are not on the federal schedules does not rely on the temporary rule, and the Medical Board notes that "DEA registration is not required to prescribe non-controlled substances." For example, testosterone is listed in Schedule III (21 CFR 1308.13) and phentermine in Schedule IV (21 CFR 1308.14), so a telehealth business prescribing either relies on these rules. State telehealth rules apply to every prescription, controlled or not: see telehealth prescribing rules.
Planning for January 1, 2027
This is our reading of what a telehealth business that prescribes controlled substances should settle before the end of the year, whatever DEA publishes:
- Which patients' prescriptions depend on 21 CFR 1307.41: those on a controlled substance who have never had an in-person evaluation by the prescriber, and are not seen by a covering practitioner.
- How those patients will get an in-person evaluation, or which statutory route applies to them, if no fifth extension is published.
- Whether patients treated for opioid use disorder fit the buprenorphine rule, including its check of the patient's state monitoring program.
- A DEA registration and a state license for each state where patients are located.
- Prescriber, platform and pharmacy agreements: who arranges and pays for in-person visits, what happens to patients mid-treatment, and how compensation is set (see the Anti-Kickback Statute for GLP-1 and peptide clinics).
- Patient-facing terms and marketing that do not promise access the rules may not allow after December 31.
Common questions
Can telehealth providers prescribe controlled substances after December 31, 2026?
Under the rules published as of November 16, 2026, only in narrower circumstances. The temporary rule allowing Schedule II-V prescriptions by telemedicine without an in-person evaluation is in effect until the end of the day on December 31, 2026. Unless DEA publishes a fifth extension or a final special registration rule, prescribers would need an in-person evaluation, a covering practitioner, or one of the telemedicine categories in 21 U.S.C. 802(54). The buprenorphine and VA rules continue.
Has DEA extended the telemedicine flexibilities again?
Not as of November 16, 2026. The latest is the fourth temporary extension (90 FR 61301, December 31, 2025), effective January 1 through December 31, 2026. No fifth extension or final special registration rule has been published in the Federal Register.
What is the DEA special registration for telemedicine?
A registration Congress authorized in 21 U.S.C. 831(h) for prescribing controlled substances by telemedicine. DEA proposed rules on January 17, 2025: three registration types, a DEA-issued State Telemedicine Registration for each state where patients are treated, an $888 fee and limits on Schedule II prescribing. The proposal has not been finalized.
Does the end of the flexibilities affect buprenorphine for opioid use disorder?
Less than other drugs. A separate final rule in effect since December 31, 2025 lets DEA-registered practitioners prescribe an initial six-month supply of Schedule III-V medications approved for opioid use disorder by telemedicine, including audio-only, after checking the prescription drug monitoring program for the patient's state. Later prescriptions need another telemedicine route or an in-person evaluation.
Do I need a DEA registration in every state where my telehealth patients are?
Generally yes, unless an exception applies. DEA's guidance and the NC Medical Board both say a prescriber generally must hold a DEA registration in the state where the patient is located at the time of care. North Carolina has no separate state controlled-substance registration.
Does this affect prescriptions for drugs that are not controlled substances?
No. The Ryan Haight Act's in-person rule and the temporary rule apply to controlled substances. Other prescriptions are governed by state law, such as the North Carolina Medical Board's telemedicine and prescribing positions.
Update log
- November 16, 2026. Published. DEA's status checked in the Federal Register (documents and public inspection) on November 16, 2026: no fifth extension and no final special registration rule. The statutes (uscode.house.gov, current through Pub. L. 119-124), the fourth temporary extension, the special registration proposal, the buprenorphine and VA rules and their delay, DEA's telemedicine guidance and web page, 21 CFR 1308.13 and 1308.14, and the NC Medical Board's DEA FAQ, all read at the source November 16, 2026.
Sources
- 21 U.S.C. 829(e) (controlled substances dispensed by means of the Internet; current through Pub. L. 119-124)
- 21 U.S.C. 802(54) (practice of telemedicine)
- 21 U.S.C. 831(h) (special registration for telemedicine)
- DEA and HHS, Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, 90 FR 61301 (Dec. 31, 2025)
- 21 CFR 1307.41 (eCFR)
- DEA, Special Registrations for Telemedicine and Limited State Telemedicine Registrations (proposed rule), 90 FR 6541 (Jan. 17, 2025)
- DEA and HHS, Expansion of Buprenorphine Treatment via Telemedicine Encounter, 90 FR 6504 (Jan. 17, 2025)
- DEA and HHS, Continuity of Care via Telemedicine for Veterans Affairs Patients, 90 FR 6523 (Jan. 17, 2025)
- DEA and HHS, delay of effective dates to December 31, 2025, 90 FR 13410 (Mar. 24, 2025)
- Federal Register, DEA documents mentioning telemedicine, newest first (checked Nov. 16, 2026)
- Federal Register, documents on public inspection (checked Nov. 16, 2026)
- DEA Diversion Control Division, Telemedicine (page undated, read Nov. 16, 2026)
- DEA Diversion Control Division, guidance document: Telemedicine (EO-DEA192, July 28, 2020)
- NC Medical Board, Professional FAQs: DEA privileges (page undated, read Nov. 16, 2026)
- 21 CFR 1308.13 (Schedule III)
- 21 CFR 1308.14 (Schedule IV)
Related
Prescribing controlled substances by telehealth?
DPS Law reviews telehealth prescribing models, prescriber, platform and pharmacy agreements, and registration plans for the end of DEA's temporary rule, under federal and North Carolina law. Our attorney is licensed in North Carolina only.